While both SGLT2i and GLP-1 RA demonstrate greater efficacy than DPP4i in lowering the risk of various cardiorenal outcomes, SGLT2i are particularly more effective than GLP-1 RA in decreasing the incidence of hospitalization for HF and renal events whereas GLP-1 RA mainly reduce the risk of nonfatal strokes [13]. The gene discussed is GCG; the disease is Stroke.